Positive outcome in clinical study to prevent radiation-induced dermatitis in breast cancer patients
APEIRON Biologics AG today announced that the clinical trial with their liposomal formulation of recombinant superoxide dismutase (project APN201) which started in March 2012 concluded with positive outcomes in all endpoints analyzed.
Below, we ask for your consent to the use of non-technically necessary cookies so that we can provide you with the best possible service on our website.
In accordance with Art 49 para 1 lit a GDPR, your consent also includes the transfers to recipients in insecure third countries, such as the USA in particular, which are described in detail in the data protection information.
You can refuse the storage of cookies that are not technically necessary in advance under "Customize cookies" or revoke your consent to storage at any time in your browser settings. By clicking on the "I agree" button, you consent to the storage of all non-technically necessary cookies.
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.